MVMD

Our team brings together world-class leadership across mucosal delivery sciences, molecular research, IP and legal management, marketing, distribution and financial services.

Our VALUE

We provide our global nutraceutical, vaccine and pharmaceutical partners with unprecedented product and market advantages.

A Decade of innovation

HELPING PEOPLE LIVE THEIR BEST LIFE.

MVMD is building a world-class biotech company centred around the implementation and licensing of our patented Quicksome™ oral delivery technologies across the global nutraceutical, vaccine and pharmaceutical landscape.

MVMD's underlying Quicksome™ technology has been in development since 2010, initially incorporated into several commercial dietary supplement products. To date, we have 14 patents in our patent portfolio, 12 extensions and have filed over a dozen provisional patents with respect to our Quicksome™ technology.

Strategy Highlights

Mountain Valley MD Strategy

Health & Wellness

We are working against leading consumer propositions that offer increased bioavailability with rapid onset across the $2 trillion USD nutraceutical, vaccine and pharmaceutical industries.

Delivery Sciences

MVMD’s advanced desiccated liposome formulations provide transmucosal delivery benefits across leading drug and vaccine application categories, including nutraceutical applications such as pain management, energy, focus, weight management, sleep, anxiety, and more.

Partner Licensing RX

Our Quicksome™ technology is available to leading nutraceutical, vaccine and pharmaceutical companies for license across a broad spectrum of molecules that provide unprecedented value propositions across their businesses.

Global Ecosystem

Our focus on strategic distribution and licensing partnerships in key markets will enable us to leverage our intellectual property, establish licensing agreements and monetize our IP rapidly.

Leading Investments

Across our delivery sciences IP portfolio and R&D work, MVMD prioritizes investment opportunities on disruptive technologies for health and wellness  applications.

Management Team

Our management team brings together world-class leadership across mucosal delivery sciences, molecular research, IP and legal management, marketing, distribution and financial services.

Our Progress

December 10, 2020

MOUNTAIN VALLEY MD CONFIRMS 800% INCREASE IN IVERMECTIN ABSORPTION WITH SOLUBILIZATION TECHNOLOGY IN PRE-CLINICAL TRIAL

Read Press Release
December 14, 2020

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES STRATEGIC PRIVATE PLACEMENT OFFERING OF UNITS, APPOINTMENT OF ADVISOR BOARD MEMBERS, AND PROPOSED DEBT SETTLEMENT

Read Press Release
December 22, 2020

MOUNTAIN VALLEY MD HOLDINGS OVERSUBSCRIBES STRATEGIC PRIVATE PLACEMENT OFFERING OF UNITS

Read Press Release
December 24, 2020

MOUNTAIN VALLEY MD FILES FOR ACCELERATION OF PATENT EXAMINATION FOR SOLUBILIZED IVERMECTIN

Read Press Release
December 29, 2020

MOUNTAIN VALLEY MD COMPLETES STRATEGIC SALE OF SUBSIDIARY, FINALIZING QUICKSOME™ LICENSE AGREEMENT

Read Press Release
January 11, 2021

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES APPLICATION FOR OTCQB LISTING IN U.S., PROVIDES UPDATE ON WARRANT EXERCISES

Read Press Release
January 14, 2021

MOUNTAIN VALLEY MD AWARDED CANADIAN PATENT FOR ITS QUICKSOME™ TECHNOLOGY

Read Press Release
Read All News

Current News

“We believe this discovery to be a breakthrough that will enable the efficacy needed to treat respiratory infections such as COVID-19, influenza and tuberculosis by enabling the drug deposition into the airways and lungs through aerosol formulations and pulmonary delivery.”

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“The extrapolation of this technology achievement across multiple viral applications could be very significant and has the potential to positively impact human and animal health globally.”

- Dennis Hancock,
  President & CEO of Mountain Valley MD
  

“A needle-free, cost-effective, polio vaccine could be a major step towards global polio eradication. Mountain Valley MD’s Quicksome™ technology has already proven its ability to stabilize and preserve the Inactivated Poliovirus Vaccine (IPV) and I believe that this technology holds great promise in finally delivering a needle-free effective sublingual polio vaccine and probably many other globally needed vaccines as well.”

- Dr. John Clements,
  Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine

“The FDA’s Polio D Antigen preservation results demonstrate that Mountain Valley MD’s proprietary and patented Quicksome™ low temperature strip manufacturing technology can be successfully applied to heat labile vaccines, complex proteins such as insulin or glucagon, peptides and other molecules and constructs that are sensitive to heat and oxidation.”

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“With encouraging FDA Polio Lab validation, Mountain Valley MD is continuing work on development of our proprietary vaccine adjuvants for Polio and the necessary pre-clinical trials to demonstrate the unprecedented impact of our Quicksome™ technology.”

- Dennis Hancock, President and CEO of Mountain Valley MD

“For decades scientists have been working to solve the problem of vaccine instability and cold chain distribution with little progress. Approaches such as micro-needle applications, lyophilization, spray drying, and others have not reached commercialization due to problems of complexity, cost, and long-term stability challenges.”

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“We believe Mountain Valley MD’s patented Quicksome™ technology revolutionizes drug and nutraceutical ingredient delivery for superior health outcomes by simultaneously addressing a multitude of key drug and nutraceutical product efficacy challenges, such as low bioavailability, high absorption variability and poor dosage control.”

- Dennis Hancock, President and CEO of Mountain Valley MD

“Many of the active ingredients contained in traditional pharmaceutical drugs and nutraceutical supplements are not well absorbed and suffer extensive degradation during first pass metabolism.  We feel this is exactly the problem that Mountain Valley MD’s direct-to-mouth Quicksome™ technology solves, dramatically improving bioavailability of compounds that are traditionally heavily metabolized by MAO enzymes, glucuronidation and other conjugation processes”.

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“We have an amazingly talented team that is working on solving some very advanced challenges in the health and wellness space.  To date we have done research and development work with more than 60 molecules for a variety of nutraceutical and pharmaceutical applications, including drugs, vaccines, the emerging mushroom space and cannabinoids.”

- Dennis Hancock, President and CEO of Mountain Valley MD

“For me personally, the idea that our delivery technology could help dispense drugs such as insulin or deliver vaccines into the body through a rapid dissolve sublingual strip and eliminate the need for painful needle injections is truly game changing.”

- Dennis Hancock, President and CEO of Mountain Valley MD
Our Progress.
Our Progress.

Subscribe for Updates

Stay plugged in on everything Mountain Valley MD.

THANK YOU FOR YOUR INTEREST IN OUR STORY.
Please check your inbox to confirm your subscription.
Oops! Something went wrong while submitting the form.
*By Clicking "Sign Up" You agree to Mountain Valley MD's Privacy Policy
Subscribe